Ischaemic postconditioning reduces infarct size: systematic review and meta-analysis of randomized controlled trials

Caroline Touboul1, Denis Angoulvant2, Nathan Mewton3

  • 1CHRU de Tours, ICCU & Cardiology department, Trousseau Hospital, 37000 Tours, France.

Insights

Cardiac ischaemic postconditioning (IPost) may reduce infarct size (IS) in ST-segment elevation myocardial infarction (STEMI) patients. This meta-analysis suggests IPost reduces IS, but larger trials are needed to confirm clinical benefits.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Biomarkers

Background:

  • Infarct size (IS) significantly impacts patient outcomes after acute ST-segment elevation myocardial infarction (STEMI).
  • Cardiac ischaemic postconditioning (IPost) is an intervention aimed at reducing reperfusion injury, potentially limiting IS.
  • IPost has demonstrated feasibility in STEMI patients undergoing primary percutaneous coronary intervention (PPCI).

Purpose of the Study:

  • To conduct an updated meta-analysis on the efficacy of IPost in reducing IS.
  • To analyze accurate surrogate markers of IS to assess IPost effectiveness.
  • To summarize current evidence on IPost for STEMI patients undergoing PPCI.

Main Methods:

  • Meta-analysis of randomized controlled trials (RCTs) evaluating IPost in STEMI patients undergoing PPCI.
  • Primary outcome: Area Under the Curve of serum creatine kinase release (CK-AUC).
  • Secondary outcomes: Other IS surrogate biomarkers, ST-segment resolution, and IS measurements via SPECT and CMR-IS.

Main Results:

  • Eleven studies with 1313 patients were included.
  • A significant reduction in CK-AUC was observed in the IPost group (SMD -2.84 IU/L, P=0.03).
  • Secondary surrogate markers, including CMR-IS, showed non-significant reductions in IS with IPost (SMD -0.36, P=0.16).

Conclusions:

  • This meta-analysis indicates that IPost reduces IS, based on surrogate markers.
  • Results require cautious interpretation due to limited sample sizes and significant heterogeneity.
  • Larger, adequately powered prospective studies are necessary to confirm clinical benefits on cardiac function and patient prognosis.
Abstract

Related Concept Videos